Management of hypertension before, during, and after pregnancy

Hypertension is the most common medical problem encountered in pregnancy and remains an important cause of maternal, and fetal, morbidity and mortality. It complicates up to 15% of pregnancies and accounts for approximately a quarter of all antenatal admissions. The hypertensive disorders of pregnancy cover a spectrum of conditions, of which pre-eclampsia poses the greatest potential risk and remains one of the most common causes of maternal death in the UK. Early in the first trimester there is a fall in blood pressure caused by active vasodilatation, achieved through the action of local mediators such as prostacyclin and nitric oxide. This reduction in blood pressure primarily affects the diastolic pressure and a drop of 10 mm Hg is usual by 13–20 weeks gestation.1 Blood pressure continues to fall until 22–24 weeks when a nadir is reached. After this, there is a gradual increase in blood pressure until term when pre-pregnancy levels are attained. Immediately after delivery blood pressure usually falls, then increases over the first five postnatal days.w1 Even women whose blood pressure was normal throughout pregnancy may experience transient hypertension in the early post partum period, perhaps reflecting a degree of vasomotor instability. Hypertension in pregnancy is diagnosed either from an absolute rise in blood pressure or from a relative rise above measurements obtained at booking. The convention for the absolute value is a systolic > 140 mm Hg or a diastolic > 90 mm Hg. However, it should be recognised that blood pressure is gestation related. A diastolic blood pressure of 90 mm Hg is 3 standard deviations (SD) above the mean for mid pregnancy, 2 SD at 34 weeks, and 1.5 SD at term.w2 The definition for a relative rise in blood pressure incorporates either a rise in systolic pressure of > 30 mm …

[1]  F. Luft,et al.  When should pregnant women with an elevated blood pressure be treated? , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  G. Prescott,et al.  Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study , 2003, BMJ : British Medical Journal.

[3]  T. Easterling,et al.  Treatment of Hypertension in Pregnancy: Effect of Atenolol on Maternal Disease, Preterm Delivery, and Fetal Growth , 2001, Obstetrics and gynecology.

[4]  J. Troendle,et al.  Risks of hypertensive disorders in the second pregnancy. , 2001, Paediatric and perinatal epidemiology.

[5]  J. Pell,et al.  Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births , 2001, The Lancet.

[6]  J. Kooner,et al.  Association of maternal endothelial dysfunction with preeclampsia. , 2001, JAMA.

[7]  F. Pipkin Risk factors for preeclampsia. , 2001, The New England journal of medicine.

[8]  A. Hagiwara,et al.  Losartan and fetal toxic effects , 2001, The Lancet.

[9]  G. H. Lambert,et al.  Transfer of drugs and other chemicals into human milk. , 2001, Pediatrics.

[10]  L. Irgens,et al.  Predicting Preeclampsia in the Second Pregnancy from Low Birth Weight in the First Pregnancy , 2000, Obstetrics and gynecology.

[11]  James J. Walker,et al.  Pre-eclampsia , 2000, The Lancet.

[12]  J. Higgins,et al.  The detection, investigation and management of hypertension in pregnancy: full consensus statement , 2000, The Australian & New Zealand journal of obstetrics & gynaecology.

[13]  G Koren,et al.  Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis , 2000, The Lancet.

[14]  R. North,et al.  Mid‐trimester uterine artery Doppler screening as a predictor of adverse pregnancy outcome in high‐risk women , 2000, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[15]  G. Hofmeyr,et al.  Bed rest in hospital for suspected impaired fetal growth. , 1996, The Cochrane database of systematic reviews.

[16]  M. Faas,et al.  Etiology and pathogenesis of preeclampsia: current concepts. , 1999, American journal of obstetrics and gynecology.

[17]  L. Poston,et al.  Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial , 1999, The Lancet.

[18]  C. Hubel,et al.  Is oxidative stress the link in the two-stage model of pre-eclampsia? , 1999, The Lancet.

[19]  R. Mann,et al.  Losartan: a study of pharmacovigilance data on 14 522 patients , 1999, Journal of Human Hypertension.

[20]  E. Seely Hypertension in pregnancy: a potential window into long-term cardiovascular risk in women. , 1999, The Journal of clinical endocrinology and metabolism.

[21]  L. Magee,et al.  Fortnightly review: management of hypertension in pregnancy. , 1999, BMJ.

[22]  R. Matijević,et al.  In vivo assessment of failed trophoblastic invasion of the spiral arteries in pre‐eclampsia , 1999, British journal of obstetrics and gynaecology.

[23]  A. Dumont,et al.  [Risk factors in pre-eclampsia]. , 1999, Presse medicale.

[24]  M. Brown,et al.  Does gestational hypertension become pre‐eclampsia? , 1998, British journal of obstetrics and gynaecology.

[25]  R. Burrows,et al.  Assessing the Teratogenic Potential of Angiotensin‐Converting Enzyme Inhibitors in Pregnancy , 1998, The Australian & New Zealand journal of obstetrics & gynaecology.

[26]  B. Sibai,et al.  Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. , 1998, The New England journal of medicine.

[27]  S. Walsh Maternal-Placental Interactions of Oxidative Stress and Antioxidants in Preeclampsia , 1998, Seminars in reproductive endocrinology.

[28]  J. Roberts,et al.  Endothelial Dysfunction in Preeclampsia , 1998, Seminars in reproductive endocrinology.

[29]  R. Kaaja Insulin Resistance Syndrome in Preeclampsia , 1998, Seminars in reproductive endocrinology.

[30]  E. Burgess,et al.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[31]  J. Penny,et al.  Blood pressure measurement in severe pre-eclampsia , 1997, The Lancet.

[32]  A. Shennan,et al.  Accuracy of oscillometric blood pressure monitoring in pregnancy and pre‐eclampsia , 1997, British journal of obstetrics and gynaecology.

[33]  S. Ferry,et al.  Cardiovascular sequelae of toxaemia of pregnancy. , 1997, Heart.

[34]  E. Ferrannini,et al.  Hyperinsulinemia in glucose-tolerant women with preeclampsia. A controlled study. , 1996, American journal of hypertension.

[35]  C. Hubel Fasting serum triglycerides, free fatty acids and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours postpartum. , 1996 .

[36]  D. Grobbee,et al.  Serum lipids in early pregnancy and risk of pre‐eclampsia , 1996, British journal of obstetrics and gynaecology.

[37]  R. North,et al.  Perinatal morbidity in chronic hypertension , 1996, British journal of obstetrics and gynaecology.

[38]  A. Halligan,et al.  Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry , 1996, The Lancet.

[39]  R. Arngrímsson,et al.  Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. , 1996, Acta obstetricia et gynecologica Scandinavica.

[40]  R. Arngrímsson,et al.  Death rates from ischemic heart disease in women with a history of hypertension in pregnancy , 1995 .

[41]  P. R. Hein,et al.  Dietary sodium restriction in the prophylaxis of hypertensive disorders of pregnancy: effects on the intake of other nutrients. , 1995, The American journal of clinical nutrition.

[42]  M. Barr,et al.  Teratogen update: angiotensin-converting enzyme inhibitors. , 1994, Teratology.

[43]  J. Whitworth,et al.  Measuring blood pressure in pregnant women: a comparison of direct and indirect methods. , 1994, American journal of obstetrics and gynecology.

[44]  R. Pijnenborg,et al.  A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre‐eclamptic pregnancies , 1994, British journal of obstetrics and gynaecology.

[45]  B. Sibai,et al.  Prevention of preeclampsia with low‐dose aspirin in healthy, nulliparous pregnant women , 1993, The New England journal of medicine.

[46]  L. Impey Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks , 1993, British journal of obstetrics and gynaecology.

[47]  B. Sibai,et al.  Eclampsia. VII. Pregnancy outcome after eclampsia and long-term prognosis. , 1992, American journal of obstetrics and gynecology.

[48]  C. Redman,et al.  Prognosis for pre-eclampsia complicated by 5 g or more of proteinuria in 24 hours. , 1992, European journal of obstetrics, gynecology, and reproductive biology.

[49]  D. Wlody,et al.  Hypertension in pregnancy. , 1992, The New England journal of medicine.

[50]  B. Sibai Diagnosis and management of chronic hypertension in pregnancy. , 1991, Obstetrics and gynecology.

[51]  J. Hargood,et al.  Pregnancy‐induced hypertension: recurrence rate in second pregnancies , 1991, The Medical journal of Australia.

[52]  Marvin Moser,et al.  Working Group Report on High Blood Pressure in Pregnancy , 2001, American journal of obstetrics and gynecology.

[53]  W. Lubbe Treatment of Hypertension in Pregnancy , 1991, Journal of cardiovascular pharmacology.

[54]  S. F. Olsen,et al.  Fish‐oil and pre‐eclampsia , 1990, British journal of obstetrics and gynaecology.

[55]  B. Sibai,et al.  A protocol for managing severe preeclampsia in the second trimester. , 1990, American journal of obstetrics and gynecology.

[56]  J. Wilson Transfer of drugs and other chemicals into human milk. , 1989, Pediatrics.

[57]  M. Brown,et al.  Capillary permeability and extracellular fluid volumes in pregnancy-induced hypertension. , 1989, Clinical science.

[58]  M. Charlson,et al.  The Prediction of Adverse Outcomes in Antepartum Hypertension , 1989 .

[59]  L. M. Mayorga,et al.  Magnesium Plus Nifedipine: Potentiation of Hypotensive Effect in Preeclampsia? , 1988, American journal of obstetrics and gynecology.

[60]  M. Thompson,et al.  Blood pressure in the puerperium. , 1986, Clinical science.

[61]  J. Bonnar,et al.  The placental bed biopsy: review from three European centers. , 1986, American journal of obstetrics and gynecology.

[62]  Sumner J. Yaffe,et al.  Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 8th Edition , 1986 .

[63]  B. Sibai,et al.  Effects of diuretics on plasma volume in pregnancies with long-term hypertension. , 1984, American journal of obstetrics and gynecology.

[64]  J. Reid,et al.  Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension. , 1983, British journal of clinical pharmacology.

[65]  T. N. Abdella,et al.  Pregnancy Outcome in 211 Patients With Mild Chronic Hypertension , 1983, Obstetrics and Gynecology.

[66]  M. J. Teague,et al.  NEW DOPPLER TECHNIQUE FOR ASSESSING UTEROPLACENTAL BLOOD FLOW , 1983, The Lancet.

[67]  C. Redman,et al.  FINAL REPORT OF STUDY ON HYPERTENSION DURING PREGNANCY: THE EFFECTS OF SPECIFIC TREATMENT ON THE GROWTH AND DEVELOPMENT OF THE CHILDREN , 1982, The Lancet.

[68]  W. Lubbe The management of hypertension in pregnancy. , 1981, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[69]  S. Hunyor,et al.  Plasma volume contraction: a significant factor in both pregnancy-associated hypertension (pre-eclampsia) and chronic hypertension in pregnancy. , 1979, The Quarterly journal of medicine.